Effects of antihypertensives on glucose metabolism

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Treatment with different antihypertensive drug classes has varied effects on glucose metabolism. Thiazide diuretic use in hypertensives has been associated with the development of glucose intolerance and diabetes. Some findings suggest that the probability of worsening glucose metabolism and the development of new diabetes after thiazide initiation is associated with increasing body mass index. Nonselective or β1 selective β-blockers may also lead to decreased insulin sensitivity in hypertensive patients. Newer β-blockers that cause vasodilatation and β-blockers that have intrinsic sympathomimetic activity may not have these deleterious effects on insulin sensitivity and glucose metabolism. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may exert beneficial effects on glycemic control through a variety of mechanisms related to the inhibition of angiotensin II. These agents may be particularly useful in patients with microalbuminuria to slow the progression of renal disease. While there may be some small differences among different classes of calcium channel blockers, there is little net effect of these agents on glucose metabolism. The prevalence of obesity, hypertension, and type 2 diabetes mellitus is increasing in the US. In this setting, it is important to individualize antihypertensive therapy and to monitor its metabolic consequences so that potential adverse effects that would negate some of the benefits of blood-pressure lowering are minimized.

Original languageEnglish (US)
Pages (from-to)211-219
Number of pages9
JournalMetabolic Syndrome and Related Disorders
Volume5
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Antihypertensive Agents
Glucose
Insulin Resistance
Thiazides
Sodium Chloride Symporter Inhibitors
Sympathomimetics
Glucose Intolerance
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Vasodilation
Angiotensin II
Type 2 Diabetes Mellitus
Disease Progression
Body Mass Index
Obesity
Blood Pressure
Hypertension
Kidney
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of antihypertensives on glucose metabolism. / Siegel, David; Swislocki, Arthur L.

In: Metabolic Syndrome and Related Disorders, Vol. 5, No. 3, 09.2007, p. 211-219.

Research output: Contribution to journalArticle

@article{e9cc1ed4c2c945ff931a44f662f02b75,
title = "Effects of antihypertensives on glucose metabolism",
abstract = "Treatment with different antihypertensive drug classes has varied effects on glucose metabolism. Thiazide diuretic use in hypertensives has been associated with the development of glucose intolerance and diabetes. Some findings suggest that the probability of worsening glucose metabolism and the development of new diabetes after thiazide initiation is associated with increasing body mass index. Nonselective or β1 selective β-blockers may also lead to decreased insulin sensitivity in hypertensive patients. Newer β-blockers that cause vasodilatation and β-blockers that have intrinsic sympathomimetic activity may not have these deleterious effects on insulin sensitivity and glucose metabolism. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may exert beneficial effects on glycemic control through a variety of mechanisms related to the inhibition of angiotensin II. These agents may be particularly useful in patients with microalbuminuria to slow the progression of renal disease. While there may be some small differences among different classes of calcium channel blockers, there is little net effect of these agents on glucose metabolism. The prevalence of obesity, hypertension, and type 2 diabetes mellitus is increasing in the US. In this setting, it is important to individualize antihypertensive therapy and to monitor its metabolic consequences so that potential adverse effects that would negate some of the benefits of blood-pressure lowering are minimized.",
author = "David Siegel and Swislocki, {Arthur L}",
year = "2007",
month = "9",
doi = "10.1089/met.2007.0016",
language = "English (US)",
volume = "5",
pages = "211--219",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Effects of antihypertensives on glucose metabolism

AU - Siegel, David

AU - Swislocki, Arthur L

PY - 2007/9

Y1 - 2007/9

N2 - Treatment with different antihypertensive drug classes has varied effects on glucose metabolism. Thiazide diuretic use in hypertensives has been associated with the development of glucose intolerance and diabetes. Some findings suggest that the probability of worsening glucose metabolism and the development of new diabetes after thiazide initiation is associated with increasing body mass index. Nonselective or β1 selective β-blockers may also lead to decreased insulin sensitivity in hypertensive patients. Newer β-blockers that cause vasodilatation and β-blockers that have intrinsic sympathomimetic activity may not have these deleterious effects on insulin sensitivity and glucose metabolism. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may exert beneficial effects on glycemic control through a variety of mechanisms related to the inhibition of angiotensin II. These agents may be particularly useful in patients with microalbuminuria to slow the progression of renal disease. While there may be some small differences among different classes of calcium channel blockers, there is little net effect of these agents on glucose metabolism. The prevalence of obesity, hypertension, and type 2 diabetes mellitus is increasing in the US. In this setting, it is important to individualize antihypertensive therapy and to monitor its metabolic consequences so that potential adverse effects that would negate some of the benefits of blood-pressure lowering are minimized.

AB - Treatment with different antihypertensive drug classes has varied effects on glucose metabolism. Thiazide diuretic use in hypertensives has been associated with the development of glucose intolerance and diabetes. Some findings suggest that the probability of worsening glucose metabolism and the development of new diabetes after thiazide initiation is associated with increasing body mass index. Nonselective or β1 selective β-blockers may also lead to decreased insulin sensitivity in hypertensive patients. Newer β-blockers that cause vasodilatation and β-blockers that have intrinsic sympathomimetic activity may not have these deleterious effects on insulin sensitivity and glucose metabolism. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may exert beneficial effects on glycemic control through a variety of mechanisms related to the inhibition of angiotensin II. These agents may be particularly useful in patients with microalbuminuria to slow the progression of renal disease. While there may be some small differences among different classes of calcium channel blockers, there is little net effect of these agents on glucose metabolism. The prevalence of obesity, hypertension, and type 2 diabetes mellitus is increasing in the US. In this setting, it is important to individualize antihypertensive therapy and to monitor its metabolic consequences so that potential adverse effects that would negate some of the benefits of blood-pressure lowering are minimized.

UR - http://www.scopus.com/inward/record.url?scp=34548610921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548610921&partnerID=8YFLogxK

U2 - 10.1089/met.2007.0016

DO - 10.1089/met.2007.0016

M3 - Article

C2 - 18370775

AN - SCOPUS:34548610921

VL - 5

SP - 211

EP - 219

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 3

ER -